Epidemiology-guided discovery of a K1-specific lytic phage with therapeutic potential against ST23-K1 multidrug-resistant hypervirulent Klebsiella pneumoniae.
Phage therapy has emerged as a promising alternative for combating multidrug-resistant hypervirulent Klebsiella pneumoniae (MDR-hvKP) infections. Recent advances suggest that tailoring phage cocktails based on genomic surveillance of circulating strains might yield more effective regimens (Koncz et al., 2024). Here, we...